BICYCLE THERAPEUTICS PLC
Close on Oct 19, 2026
- Market cap
- $246.76M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Earnings
Next report expected Oct 29, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 30, 2026 | Before market open | $629.00K | $-0.72 | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | Before market open | $900.00K | $-0.87 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 17, 2026 | Before market open | $48.00M | $-0.29 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 30, 2025 | Before market open | $11.73M | $-0.85 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 8, 2025 | Before market open | $2.92M | $-1.14 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 1, 2025 | Before market open | $9.98M | $-0.88 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 25, 2025 | Before market open | $3.71M | $-0.75 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 31, 2024 | Before market open | $2.68M | $-0.74 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 20, 2024 | Before market open | – | – | – |
Press releases
Announcements Bicycle Therapeutics filed with the SEC
Bicycle Therapeutics Reports Recent Business
Results of operations · EX-99.1 to Form 8-K
Bicycle Therapeutics to Present Initial Duravelo-2
Other events · EX-99.1 to Form 8-K
Bicycle Therapeutics Reports Recent Business
Results of operations · EX-99.1 to Form 8-K
Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026
Other events · EX-99.1 to Form 8-K
Bicycle Therapeutics Reports Recent Business Progress and Fourth
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Bicycle Therapeutics Highlights 2025 Accomplishments
Other events · EX-99.1 to Form 8-K
Bicycle Therapeutics Reports Recent Business
Results of operations · EX-99.1 to Form 8-K
Bicycle Therapeutics Reports Recent Business
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Bicycle Therapeutics Reports Recent Business
Results of operations · EX-99.1 to Form 8-K
of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Bicycle Therapeutics Announces New Board and
Executive or director change · Other events · EX-99.1 to Form 8-K
Bicycle Therapeutics Reports Recent Business
Results of operations · EX-99.1 to Form 8-K
Bicycle Therapeutics Announces Updated Topline
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Bicycle Therapeutics Announces Data Updates
Other events · EX-99.1 to Form 8-K
Bicycle Therapeutics Reports Recent Business
Results of operations · EX-99.1 to Form 8-K
Bicycle Therapeutics Announces First Human Imaging
Other events · EX-99.1 to Form 8-K
Bicycle Therapeutics Presents Updated Clinical
Other events · EX-99.1 to Form 8-K
Bicycle Therapeutics Reports Recent Business
Results of operations · EX-99.1 to Form 8-K
Bicycle Therapeutics Reports Recent Business
Results of operations · EX-99.1 to Form 8-K
Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Bicycle Therapeutics Provides Data Updates for
Other events · EX-99.1 to Form 8-K
Bicycle Therapeutics Reports Recent Business
Results of operations · EX-99.1 to Form 8-K
Bicycle Therapeutics Announces Expedited Development
Other events · EX-99.1 to Form 8-K
Bicycle Therapeutics Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
Bicycle Therapeutics Reports First Quarter 2023
Results of operations · EX-99.1 to Form 8-K
Bicycle Therapeutics Enhances Leadership Team
Other events · EX-99.1 to Form 8-K
Bicycle Therapeutics Reports Fourth Quarter
Results of operations · EX-99.1 to Form 8-K
Bicycle Therapeutics Announces Phase I Dose
Other events · EX-99.1 to Form 8-K
Bicycle Therapeutics Announces First Patient
Other events · EX-99.1 to Form 8-K
Bicycle Therapeutics Reports Third Quarter 2022
Results of operations · EX-99.1 to Form 8-K
Bicycle Therapeutics Announces BT5528 Phase
Other events · EX-99.1 to Form 8-K
Bicycle Therapeutics Reports Second Quarter 2022
Results of operations · Other events · EX-99.1 to Form 8-K
Bicycle Therapeutics Announces Further Expansion
Other events · EX-99.1 to Form 8-K
Bicycle Therapeutics Reports First Quarter 2022
Results of operations · Other events · EX-99.1 to Form 8-K
Bicycle Therapeutics Announces Interim BT8009
Other events · EX-99.1 to Form 8-K
BT8009 clinical trial update NASDAQ: BCYC April 2022 Exhibit 992 SP1
Other events · EX-99.2 to Form 8-K
Bicycle Therapeutics Reports Fourth Quarter
Results of operations · EX-99.1 to Form 8-K
Bicycle Therapeutics Announces Continued Clinical
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Bicycle Therapeutics Reports Third Quarter 2021
Results of operations · Other events · EX-99.1 to Form 8-K
Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle ®
Results of operations · Other events · EX-99.2 to Form 8-K